Therakos ECP Immunomodulation - Homepage

user sign in

EN

EN
DE
IT
ES

My Therakos

Languages:

Therakos e-learning platform

WELCOME TO
THE HOME OF ECP

DISCOVER MORE ABOUT THE PIONEERS OF ECP IMMUNOMODULATION

DISCOVER OUR FULL EDUCATIONAL OFFER INCLUDING
CENTRES OF EXCELLENCE, WEBINARS, SPEAKER MEETINGS AND MORE

REGISTER NOW

GET ACCESS TO THE THERAKOS INSTITUTE, E-LEARNING PLATFORM AND MYTHERAKOS TO KEEP UP TO DATE WITH THERAKOS ECP IMMUNOMODULATION^TM

FOLLOW US AND STAY UP TO DATE WITH THE LATEST NEWS AND EVENTS IN ECP EDUCATION

The Therakos Institute

Introducing

The Therakos Institute

Read more

Discover

Our Upcoming
Webinars

Register Here

Take a look at

Our On Demand Webinars

See More

14 October 2021

Immunomodulation in acute GvHD: a fit for ECP?

23 June 2021

Management of cGvHD: How supportive care can help

Upcoming

Events

Discover More

DISCOVER OUR
CELLEX^TM SYSTEM

The world’s only fully integrated and validated ECP system

Discover More

OUR
LEGACY

We are the pioneers of ECP, and have been for over 30 years. Find out what this means for you.

Discover More

HEALTHCARE
PROFESSIONALS

Find out about our full range of services tailored to you.

Discover More

PATIENTS AND
CAREGIVERS

Discover more about extracorporeal photopheresis and see our patient support materials.

Discover More

Upcoming Congresses

2-4 September, 2022

Barcelona

7th International Transplant Course Barcelona

Read more

22–24 September, 2022

Madrid

EORTC

Read more

22-23 September, 2022

London

Autoimmune Diseases Working Party Educational Meeting

Read more

29 September-1 October, 2022

Berlin

Transplant Complications Working Party Educational Meeting

Read more

6-7 October, 2022

Brussels

14th Nurses International Study Day & 6th Nurses Research Day

Read more

The 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)

27-30 October, 2022

Berlin & Virtual

COSTEM 2022

Read more

Important Safety Information
For the Therakos^TM Photopheresis
Procedure

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease.
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³.
Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOS^TM CELLEX^TMPhotopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.